Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-06-03
DOI
10.1016/s1470-2045(22)00273-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
- (2022) Wilfredo F. Garcia-Beltran et al. CELL
- Emerging evidence on Omicron (B.1.1.529) SARS‐CoV‐2 variant
- (2022) Vineet Sharma et al. JOURNAL OF MEDICAL VIROLOGY
- SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo
- (2022) Kenrie P. Y. Hui et al. NATURE
- SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein–ACE2 complex
- (2022) Dhiraj Mannar et al. SCIENCE
- Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer
- (2021) Alfredo Addeo et al. CANCER CELL
- Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study
- (2021) David J. Pinato et al. EUROPEAN JOURNAL OF CANCER
- SARS-CoV-2 variants, spike mutations and immune escape
- (2021) William T. Harvey et al. NATURE REVIEWS MICROBIOLOGY
- Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
- (2021) Yinon M. Bar-On et al. NEW ENGLAND JOURNAL OF MEDICINE
- Understanding COVID-19 vaccine hesitancy and resistance: another challenge in cancer patients
- (2021) Nesrine Mejri et al. SUPPORTIVE CARE IN CANCER
- COVID-19 and Cancer
- (2021) Aakash Desai et al. JAMA Oncology
- Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer
- (2021) Lauren C. Shapiro et al. CANCER CELL
- Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer
- (2021) Annika Fendler et al. CANCER CELL
- Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves
- (2021) Caroline Maslo et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses
- (2021) Valérie Gounant et al. Journal of Thoracic Oncology
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
- (2021) Alasdair P S Munro et al. LANCET
- mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
- (2021) Sjoukje F Oosting et al. LANCET ONCOLOGY
- Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study
- (2021) David J Pinato et al. LANCET ONCOLOGY
- Tracking the Emergence of SARS-CoV-2 Alpha Variant in the United Kingdom
- (2021) A. Sarah Walker et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells
- (2021) Hanjun Zhao et al. Emerging Microbes & Infections
- Time-Dependent COVID-19 Mortality in Patients With Cancer
- (2021) et al. JAMA Oncology
- COVID-19 vaccination and breakthrough infections in patients with cancer
- (2021) A.L. Schmidt et al. ANNALS OF ONCOLOGY
- Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019
- (2020) Juanjuan Zhao et al. CLINICAL INFECTIOUS DISEASES
- Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
- (2020) Stephen M. Kissler et al. SCIENCE
- COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
- (2020) Marina Chiara Garassino et al. LANCET ONCOLOGY
- Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients.
- (2020) David J Pinato et al. Cancer Discovery
- Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe
- (2020) David J. Pinato et al. Cancers
- COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
- (2020) Lennard Y W Lee et al. LANCET ONCOLOGY
- Influenza Virus Evolution, Host Adaptation, and Pandemic Formation
- (2010) Jeffery K. Taubenberger et al. Cell Host & Microbe
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started